HMGB1 and cutaneous melanoma: Similarly, early experimental results regarding an anti‐inflammatory role of HMGB1 inhibition in atopic dermatitis112 could prompt the development of an anti‐HMGB1 monoclonal antibody for that condition, thus further encouraging the already nascent research on HMGB1 use as a target in cutaneous melanoma (Table 1).